Filing Summary
Issuer identity warning: The request identifies Nexttrip, Inc., but the supplied filing is Sigma Labs, Inc. (Nasdaq: SGLB), a Nevada company. This summary reflects the supplied filing and may not relate to Nexttrip.
Business Context and Reporting Period
Sigma Labs develops and commercializes manufacturing quality-assurance and process-control technologies, including its PrintRite3D products for metal additive manufacturing. This unaudited Form 10-Q covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021; balance-sheet comparisons are to December 31, 2021.
Financial Results and Liquidity
| Metric | Q1 2022 | Q1 2021 / comparator |
|---|---|---|
| Revenue | $51,844 | $458,140 |
| Gross profit (gross margin) | $11,753 (22.7%) | $329,809 (72.0%) |
| Operating expenses | $2,295,698 | $1,781,404 |
| Operating loss | $(2,283,945) | $(1,451,595) |
| Net loss | $(2,207,395) | $(650,659) |
| Net loss applicable to common stockholders; loss per share | $(2,221,615); $(0.21) | $(711,567); $(0.09) |
| Cash used in operating activities | $(2,027,019) | $(1,240,586) |
| Cash and working capital | $9,277,929 cash; $9,588,858 working capital at March 31, 2022 | $11,447,047 cash; $11,702,358 working capital at December 31, 2021 |
Cash used in investing activities was $142,099; there was no financing cash flow in Q1 2022. Total liabilities were $897,466, all reported as current liabilities; the balance sheet lists no borrowings. The company reported no lines of credit or other financing arrangements. A $37,728 deferred Social Security tax balance was due by December 31, 2022 at 0% interest.
Material Changes and Management Commentary
- Revenue fell 89%, primarily because PrintRite3D unit sales declined by $416,500; subscription revenue increased by $13,425.
- Operating expenses rose 29%, chiefly from higher salaries and benefits associated with hiring and compensation increases. The operating loss widened by $832,350.
- Net loss applicable to common stockholders increased by $1,510,048. The comparison was also affected by the absence of the prior-year $802,285 gain from revaluing warrant derivative liabilities; Q1 2022 included $76,628 of New Mexico state incentives.
- Management described a three-year strategy to lower customer acquisition costs through subscription pricing, expand OEM partnerships, and move toward software-only embedded offerings. Management said this transition weighed on near-term revenue but is intended to support adoption and more predictable, profitable revenue over time.
- Management stated that available cash was expected to fund anticipated operating costs and capital expenditures through at least Q1 2023, while cautioning that assumptions could prove incorrect. It expects to fund operations and commercialization using cash reserves and revenue, but notes that future funding needs depend on commercialization, partnerships, expenses, and market developments.
Risks, Contingencies, and Other Items
- The company cited commercialization and revenue-generation uncertainty, dependence on adoption of additive manufacturing and PrintRite3D, and possible need for additional capital. It warned that failure to obtain funding could require delaying or scaling back operations; additional securities could dilute shareholders or have senior rights.
- Management noted uncertainty from COVID-19 and its variants, potential effects on customer spending and capital-market access, and possible effects from geopolitical events, including the conflict in Ukraine.
- Outstanding Series D and Series E convertible preferred shares accrue dividends at 9% annually and have conversion provisions; Series D terms also provide for possible holder redemption at a premium upon specified triggering events.
- Potential dilution includes 3,825,781 warrants, 1,547,797 stock options, and 148,918 preferred-stock underlying shares excluded from diluted loss per share as anti-dilutive. No material subsequent events were reported through the filing date. Legal proceedings were reported as not applicable.
- Management concluded disclosure controls and procedures were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Most Important Facts to Verify
- Confirm the intended issuer: the supplied filing is for Sigma Labs, Inc., not Nexttrip, Inc.
- Verify the drivers and sustainability of the sharp revenue decline, and progress in subscription and OEM programs.
- Assess cash burn against management’s stated runway through at least Q1 2023, particularly given the lack of Q1 financing proceeds.
- Review the terms, potential dilution, and redemption or conversion implications of preferred stock, warrants, options, and stock-appreciation rights.
- Review the company’s latest filings for changes to its commercialization plans, funding outlook, and risk disclosures.